Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.43 |
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | THPO | P40225 | 1/20 | 0.36 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.36 |
| ▸ | LCK | P06239 | 1/20 | 0.36 |
| ▸ | FYN | P06241 | 1/20 | 0.36 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.35 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.35 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.31 |
| ▸ | GABRP | O00591 | 4/20 | 0.30 |
| ▸ | GABRD | O14764 | 4/20 | 0.30 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.30 |
| ▸ | GABRB1 | P18505 | 4/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18286558 | 1.00 | LMNA (0.43) | LMNAALOX15BLMPMP22SLC7A5 | |
| SCHEMBL4291960 | 0.87 | SLC7A5 (0.55) | LMNAALOX15BLMPMP22SLC7A5 | |
| SCHEMBL5868322 | 0.87 | LMNA (0.41) | LMNAALOX15BLMPMP22SLC7A5 | |
| SCHEMBL10291869 | 0.85 | — | — | |
| SCHEMBL10056813 | 0.85 | — | — | |
| SCHEMBL825007 | 0.85 | — | — | |
| Hydrochloric Acid SCHEMBL8127228 | 0.82 | — | — | |
| SCHEMBL17282365 | 0.80 | TDP1 (0.38) | SLC7A5FFAR3TDP1GRIK1ALDH1A1 | |
| SCHEMBL23748424 | 0.79 | — | — | |
| SCHEMBL12940444 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4229173-A | — | — | None | — | — | JP | disclosed |
| CN-116425753-A | Pyrrolizine skeleton pyrimidine ring substituted derivative, preparation method thereof and flow battery | 西安交通大学 | 2023-07-14 | — | — | CN | disclosed |
| US-20170144998-A1 | ELASTASE INHIBITORS | THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH | 2017-05-25 | — | — | US | disclosed |
| JP-H04229173-A | DIACETYLPOLYAMINE AMIDOHYDROLASE | TOKUYAMA SODA CO LTD | 1992-08-18 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170144998-A1 | ELASTASE INHIBITORS | SERPINB1, ELANE, CELA1 | LMNA 694/4885ALOX15 575/4885BLM 539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.